Early exposures and inherent factors in premature newborns are associated with type 1 diabetes.


Journal

Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 02 10 2020
accepted: 27 02 2022
revised: 08 02 2022
pubmed: 30 4 2022
medline: 30 4 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

Pathophysiology of type 1 diabetes (T1D) involves immune responses that may be associated with early exposure to environmental factors among preterm newborns. The aim of this work was to evaluate for association between T1D and maternal, nutritional, and medical exposures during the neonatal period among premature newborns. This is a multicenter, matched case-control study. Preterm newborns, who developed T1D before 18 years, were matched by sex, gestational age (GA), birth date, and medical center of birth with newborns who did not develop TID. Data included maternal medical history, birth weight (BW), length of hospitalization, enteral and parenteral medications, fluid administration, and feeding modalities during hospitalization. Fifty-two patients with T1D, 26 males, median age at T1D diagnosis 8.17 years (5.92-9.77), median GA 34 weeks (33-m36), and 132 matched controls, were included. Multivariate-conditional-regression demonstrated a significant association between T1D and any maternal illness (23.1% vs. 9.1%, OR = 4.99 (1.69-14.72), p = 0.004), higher BW-SDS (0.07 ± 0.95 vs. -0.27 ± 0.97, OR = 2.03 (1.19-3.49), p = 0.01), longer duration of glucose infusion (3 (1-5) days vs. 2 (0-4), OR = 1.23 (1.03-1.46), p = 0.02), and antibiotic therapy beyond the first week of life (19.2% vs. 6.9%, OR = 5.22 (1.32-20.70), p = 0.019). Antibiotic treatment during the first week of life was negatively associated with T1D (51.9% vs. 67.2%, OR 0.31 (0.11-0.88), p = 0.027). A novel association was demonstrated between the development of T1D and early interventions and exposures among preterm newborns. Type 1 diabetes mellitus during childhood may be associated with early exposures during the neonatal period, in addition to known maternal and neonatal metabolic parameters. Early exposure to intravenous antibiotics, differing between the first week of life and later, and longer parenteral glucose administration to preterm newborns were associated with childhood type 1 diabetes. This is in addition to familiar maternal risk factors. Future prospective studies should examine the microbial changes and immune system characteristics of preterm and term neonates exposed to parenteral antibiotics and glucose treatment, in order to validate our exploratory findings.

Sections du résumé

BACKGROUND BACKGROUND
Pathophysiology of type 1 diabetes (T1D) involves immune responses that may be associated with early exposure to environmental factors among preterm newborns. The aim of this work was to evaluate for association between T1D and maternal, nutritional, and medical exposures during the neonatal period among premature newborns.
METHODS METHODS
This is a multicenter, matched case-control study. Preterm newborns, who developed T1D before 18 years, were matched by sex, gestational age (GA), birth date, and medical center of birth with newborns who did not develop TID. Data included maternal medical history, birth weight (BW), length of hospitalization, enteral and parenteral medications, fluid administration, and feeding modalities during hospitalization.
RESULTS RESULTS
Fifty-two patients with T1D, 26 males, median age at T1D diagnosis 8.17 years (5.92-9.77), median GA 34 weeks (33-m36), and 132 matched controls, were included. Multivariate-conditional-regression demonstrated a significant association between T1D and any maternal illness (23.1% vs. 9.1%, OR = 4.99 (1.69-14.72), p = 0.004), higher BW-SDS (0.07 ± 0.95 vs. -0.27 ± 0.97, OR = 2.03 (1.19-3.49), p = 0.01), longer duration of glucose infusion (3 (1-5) days vs. 2 (0-4), OR = 1.23 (1.03-1.46), p = 0.02), and antibiotic therapy beyond the first week of life (19.2% vs. 6.9%, OR = 5.22 (1.32-20.70), p = 0.019). Antibiotic treatment during the first week of life was negatively associated with T1D (51.9% vs. 67.2%, OR 0.31 (0.11-0.88), p = 0.027).
CONCLUSIONS CONCLUSIONS
A novel association was demonstrated between the development of T1D and early interventions and exposures among preterm newborns.
IMPACT CONCLUSIONS
Type 1 diabetes mellitus during childhood may be associated with early exposures during the neonatal period, in addition to known maternal and neonatal metabolic parameters. Early exposure to intravenous antibiotics, differing between the first week of life and later, and longer parenteral glucose administration to preterm newborns were associated with childhood type 1 diabetes. This is in addition to familiar maternal risk factors. Future prospective studies should examine the microbial changes and immune system characteristics of preterm and term neonates exposed to parenteral antibiotics and glucose treatment, in order to validate our exploratory findings.

Identifiants

pubmed: 35488031
doi: 10.1038/s41390-022-02069-w
pii: 10.1038/s41390-022-02069-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1516-1522

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.

Références

Burrack, A. L., Martinov, T. & Fife, B. T. T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes. Front. Endocrinol. 8, 1 (2017).
doi: 10.3389/fendo.2017.00343
Honkanen, J. et al. IL-17 immunity in human type 1 diabetes. J. Immunol. 185, 1959–1967 (2010).
doi: 10.4049/jimmunol.1000788 pubmed: 20592279
Vaarala, O. Is the origin of type 1 diabetes in the gut? Immunol. Cell Biol. 90, 271–276 (2012).
doi: 10.1038/icb.2011.115 pubmed: 22290506
Nyaga, D. M., Vickers, M. H., Jefferies, C., Perry, J. K. & O’Sullivan, J. M. The genetic architecture of type 1 diabetes mellitus. Mol. Cell. Endocrinol. 477, 70–80 (2018).
doi: 10.1016/j.mce.2018.06.002 pubmed: 29913182
Barker, D. J. P. & Osmond, C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. Lancet 327, 1077–1081 (1986).
doi: 10.1016/S0140-6736(86)91340-1
Kuchlbauer, V. et al. High birth weights but not excessive weight gain prior to manifestation are related to earlier onset of diabetes in childhood: ‘accelerator hypothesis’ revisited. Pediatr. Diabetes 15, 428–435 (2014).
doi: 10.1111/pedi.12107 pubmed: 24350794
Wadsworth, E. J. K., Shield, J. P. H., Hunt, L. P. & Baum, J. D. A case‐control study of environmental factors associated with diabetes in the under 5s. Diabet. Med. 14, 390–396 (1997).
doi: 10.1002/(SICI)1096-9136(199705)14:5<390::AID-DIA364>3.0.CO;2-E pubmed: 9171256
Dahlquist, G. & Källén, B. Maternal-child blood group incompatibility and other perinatal events increase the risk for early-onset type 1 (insulin-dependent) diabetes mellitus. Diabetologia 35, 671–675 (1992).
doi: 10.1007/BF00400261 pubmed: 1644246
Lee, H.-Y., Lu, C.-L., Chen, H.-F., Su, H.-F. & Li, C.-Y. Perinatal and childhood risk factors for early-onset type 1 diabetes: a population-based case-control study in Taiwan‏. Eur. J. Public Health 25, 1024–1029 (2015)‏.
Dahlquist, G., Savilahti, E. & Landin-Olsson, M. An increased level of antibodies to β-ltoglobulin is a risk determinant for early-onset Type 1 (insulin-dependent) diabetes mellitus independent of islet cell antibodies and early introduction of cow’s milk. Diabetologia 35, 980–984 (1992).
doi: 10.1007/BF00401429 pubmed: 1451957
Ziegler, A. G., Schmid, S., Huber, D., Hummel, M. & Bonifacio, E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. J. Am. Med. Assoc. 290, 1721–1728 (2003).
doi: 10.1001/jama.290.13.1721
Xia, Y., Xie, Z., Huang, G. & Zhou, Z. Incidence and trend of type 1 diabetes and the underlying environmental determinants. Diabetes Metab. Res. Rev. 35, e3075 (2019).
doi: 10.1002/dmrr.3075 pubmed: 30207035
Adi, A. et al. Birth during the moderate weather seasons is associated with early onset of type 1 diabetes in the mediterranean area. Diabetes. Metab. Res. Rev. https://doi.org/10.1002/dmrr.3318 (2020).
Zheng, P., Li, Z. & Zhou, Z. Gut microbiome in type 1 diabetes: a comprehensive review. Diabetes Metab. Res. Rev. 34, e3043 (2018).
doi: 10.1002/dmrr.3043 pubmed: 29929213 pmcid: 6220847
Wen, L. et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455, 1109–1113 (2008).
doi: 10.1038/nature07336 pubmed: 18806780 pmcid: 2574766
Valladares, R. et al. Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS ONE 5, e10507 (2010).
Hänninen, A. et al. Islet β-cell-specific T cells can use different homing mechanisms to infiltrate and destroy pancreatic islets. Am. J. Pathol. 170, 240–250 (2007).
doi: 10.2353/ajpath.2007.060142 pubmed: 17200197 pmcid: 1762684
Jaberi-Douraki, M., Liu, S. W. S., Pietropaolo, M. & Khadra, A. Autoimmune responses in T1DM: quantitative methods to understand onset, progression, and prevention of disease. Pediatr. Diabetes 15, 162–174 (2014).
doi: 10.1111/pedi.12148 pubmed: 24827702 pmcid: 4050373
Ziegler, A. G. et al. Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J. Autoimmun. 37, 3–7 (2011).
doi: 10.1016/j.jaut.2011.02.004 pubmed: 21376535 pmcid: 3110538
Gritz, E. C. & Bhandari, V. The human neonatal gut microbiome: a brief review. Front. Pediatr. 3, 17 (2015).
pubmed: 25798435 pmcid: 4350424
Knip, M. et al. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial. JAMA 319, 38–48 (2018).
doi: 10.1001/jama.2017.19826 pubmed: 29297078 pmcid: 5833549
Knip, M. et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N. Engl. J. Med. 363, 1900–1908 (2010).
Vaarala, O. et al. Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch. Pediatr. Adolesc. Med. 166, 608–614 (2012).
doi: 10.1001/archpediatrics.2011.1559 pubmed: 22393174
Sudo, N. et al. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J. Immunol. 159, 1739–1745 (1997).
doi: 10.4049/jimmunol.159.4.1739 pubmed: 9257835
Egro, F. M. Why is type 1 diabetes increasing? J. Mol. Endocrinol. 51, 1–13 (2013).
doi: 10.1530/JME-13-0067
Blumenfeld, O. et al. Trends in the incidence of type 1 diabetes among Jews and Arabs in Israel. Pediatr. Diabetes 15, 422–427 (2014).
doi: 10.1111/pedi.12101 pubmed: 24283719
Adar, A. et al. Prevalence of early and late prematurity is similar among pediatric type 1 diabetes patients and the general population. Diabetes. Metab. Res. Rev. 34, e2996 (2018).
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 37, S81–S90 (2014).
PediTools. Fenton 2013 growth calculator for preterm infants. https://peditools.org/fenton2013/ (2013).
Gelman, A., Hill, J. & Yajima, M. Why we (usually) don’t have to worry about multiple comparisons. J. Res. Educ. Eff. 5, 189–211 (2012).
Rothman, K. J. No adjustments are needed for multiple comparisons. Epidemiology 1, 43–46 (1990).
doi: 10.1097/00001648-199001000-00010 pubmed: 2081237
Althouse, A. D. Adjust for multiple comparisons? It’s not that simple. Ann. Thorac. Surg. 101, 1644–1645 (2016).
doi: 10.1016/j.athoracsur.2015.11.024 pubmed: 27106412
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R. & Feinstem, A. R. A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 49, 1373–1379 (1996).
doi: 10.1016/S0895-4356(96)00236-3 pubmed: 8970487
Virtanen, S. M. et al. Microbial exposure in infancy and subsequent appearance of type 1 diabetes mellitus-associated autoantibodies a cohort study. JAMA Pediatr. 168, 755–763 (2014).
doi: 10.1001/jamapediatrics.2014.296 pubmed: 24957949
Kemppainen, K. et al. Association between early-life antibiotic use and the risk of islet or celiac disease autoimmunity. JAMA Pediatr. 171, 1217–1225 (2013).
Tapia, G. et al. Antibiotics, acetaminophen and infections during prenatal and early life in relation to type 1 diabetes‏. Int. J. Epidemiol. 47, 1538–1548 (2018).
Boursi, B., Mamtani, R., Haynes, K. & Yang, Y. X. The effect of past antibiotic exposure on diabetes risk. Eur. J. Endocrinol. 172, 639–648 (2015).
doi: 10.1530/EJE-14-1163 pubmed: 25805893 pmcid: 4525475
Zhang, X. S. et al. Antibiotic-induced acceleration of type 1 diabetes alters maturation of innate intestinal immunity. Elife 7, e37816 (2018).
Uzan-Yulzari, A. et al. Neonatal antibiotic exposure impairs child growth during the first six years of life by perturbing intestinal microbial colonization. Nat. Commun. 12, 1–12 (2021).
doi: 10.1038/s41467-020-20495-4
El-Aidy, S., Hooiveld, G., Tremaroli, V., Bäckhed, F. & Kleerebezem, M. The gut microbiota and mucosal homeostasis: colonized at birth or at adulthood, does it matter? Gut Microbes 4, 118–124 (2013).
doi: 10.4161/gmic.23362 pubmed: 23333858 pmcid: 3595071
Johnson, C. L. & Versalovic, J. The human microbiome and its potential importance to pediatrics. Pediatrics 129, 950–960 (2012).
doi: 10.1542/peds.2011-2736 pubmed: 22473366 pmcid: 3340594
Kostic, A. et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe 17, 260–273 (2015).
Walker, W.-A. Initial intestinal colonization in the human infant and immune homeostasis. Ann. Nutr. Metab. 63, 8–15 (2013)‏.
Vatanen, T. et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 562, 589–594 (2018).
doi: 10.1038/s41586-018-0620-2 pubmed: 30356183 pmcid: 6296767
De Goffau, M. C. et al. Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia 57, 1569–1577 (2014).
doi: 10.1007/s00125-014-3274-0 pubmed: 24930037
Sommer, F. & Bäckhed, F. The gut microbiota-masters of host development and physiology. Nat. Rev. Microbiol. https://doi.org/10.1038/nrmicro2974 (2013).
Arboleya, S. et al. Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics. J. Pediatr. 166, 538–544 (2015).
doi: 10.1016/j.jpeds.2014.09.041 pubmed: 25444008
Modi, S. R., Collins, J. J. & Relman, D. A. Antibiotics and the gut microbiota. J. Clin. Investig. 124, 4212–4218 (2014).
doi: 10.1172/JCI72333 pubmed: 25271726 pmcid: 4191029
Grill, V. & Björklund, A. Overstimulation and beta-cell function. Diabetes 50(Suppl 1), S122–S124 (2001).
Scaglia, L., Cahill, C. J., Finegood, D. T. & Bonner-Weir, S. Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology 138, 1736–1741 (1997).
doi: 10.1210/endo.138.4.5069 pubmed: 9075738
Kassem, S. A., Ariel, I., Thornton, P. S., Scheimberg, I. & Glaser, B. Cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes 49, 1325–1333 (2000).
Petrik, J., Arany, E., McDonald, T. J. & Hill, D. J. Apoptosis in the pancreatic islet cells of the neonatal rat is associated with a reduced expression of insulin-like growth factor II that may act as a survival factor. Endocrinology 139, 2994–3004 (1998).
doi: 10.1210/endo.139.6.6042 pubmed: 9607811
Burattini, I. et al. Targeting 2.5 versus 4 g/kg/day of amino acids for extremely low birth weight infants: a randomized clinical trial. J. Pediatr. 163, 1278.e1–1282.e1 (2013).
doi: 10.1016/j.jpeds.2013.06.075
Wu, R.-Q., Zhang, D.-F, Tu, E., Chen, Q.-M. & Chen, W. The mucosal immune system in the oral cavity—an orchestra of T cell diversity. Int. J. Oral Sci. 6, 125–132 (2014)‏.

Auteurs

Iren Zargari (I)

Pediatric Endocrinology Unit, Division of Pediatrics, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Adi Adar (A)

Pediatric Endocrinology Unit, Division of Pediatrics, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Iris Morag (I)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Neonatal Intensive Care Unit, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.

Orit Pinhas-Hamiel (O)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatric Endocrinology and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.

Ori Eyal (O)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Rimona Keidar (R)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Neonatal Intensive Care Unit, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel.

Neta Loewenthal (N)

Pediatric Endocrinology and Metabolic Unit, Soroka University Medical Center, Beer Sheva, Israel.

Milana Levy (M)

Pediatric Diabetes and Obesity Clinic, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.

Orna Dally-Gottfried (O)

The Center for Juvenile Diabetes and Pediatric Endocrinology and Pediatric Outpatient Clinics, Rebecca Ziv Hospital, affiliated to The School of Medicine, Bar Ilan University, Safed, Israel.

Zohar Landau (Z)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatric Endocrinology and Diabetes Unit, E. Wolfson Medical Center, Holon, Israel.

Floris Levy-Khademi (F)

The School of Medicine in the Hebrew University of Jerusalem, Jerusalem, Israel.
Division of Pediatric Endocrinology, Shaare Zedek Medical Center, Jerusalem, Israel.

Smadar Eventov-Friedman (S)

The School of Medicine in the Hebrew University of Jerusalem, Jerusalem, Israel.
Neonatal Intensive Care Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

David Zangen (D)

The School of Medicine in the Hebrew University of Jerusalem, Jerusalem, Israel.
Division of Pediatric Endocrinology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Ilan Youngster (I)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatric Infectious Diseases Unit, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel.

Marianna Rachmiel (M)

Pediatric Endocrinology Unit, Division of Pediatrics, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel. mariannar@shamir.gov.il.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. mariannar@shamir.gov.il.

Classifications MeSH